Summit Therapeutics Cash Flow - Annual (NASDAQ:SMMT)

Add to My Stocks
$2.32 $0.01 (0.43%) SMMT stock closing price Sep 18, 2018 (Closing)

For analyzing any company like Summit Therapeutics from an investment perspective, its important to check the cash flow statement. While its important to look at the Summit Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Summit Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Summit Therapeutics had cash and cash equivalents of $36.51M at beginning of the year and $26.16M at year end for 2018. Summit Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Summit Therapeutics has a negative cash and cash equivalents change of $-10.35M.

View details of Summit Therapeutics cash flows for latest & last 10 financial years
show more
Fiscal year is Feb - Jan2018201720162015
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----
Net Increase (Decrease) in Assets Liabilities-10.54M42.58M--0.54M
Cash From (used in) Discontinued Operations----
Other Adjustments Net5.28M7.97M3.57M2.67M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.46M-0.1M-0.1M-0.05M
Acquisition Disposition of Subsidiaires-6.21M---
Increase (Decrease) in Investments----
Other Cash Inflow (Outflow) from Investment Activities-0.13M---
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares19.94M-40.07M36.05M
Issuance (Repayment) of Debt Securities----
Increase (Decrease) in Bank & Other Borrowings----
Payment of Dividends & Other Cash Distributions----
Other Cash from (used by) Financing Activities-1.84M--6.37M-2.42M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-2.51M-0.95M--
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year36.51M21.81M17.15M3.32M
Cash & Equivalents at Year End26.16M37.54M24.82M18.43M
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Shire financial analysis

While Summit Therapeutics stock price history provides the price history of a stock, Summit Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Summit Therapeutics has cash of $26.16M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Summit Therapeutics stock price.
  • Cash Flow from operating activities: Summit Therapeutics reported a negative operating cash flow of $-19.11M for 2018 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-6.82M for SMMT stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Summit Therapeutics earned $18.09M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Summit Therapeutics Cash Flow

Annual Cash Flow Statements For Summit Therapeutics PLC (ADR) Peers

Can-Fite Biopharma cash flow, IsoRay cash flow, JAGUAR HEALTH cash flow, Kitov Pharma cash flow, Shire cash flow